Histone Deacetylase Inhibitors

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 859-879

  Finn, Paul W ^a  

^a INHIBOX LTD   (United Kingdom)

Author keywords

HDAC inhibitors in therapeutic applications; Histone deacetylases (HDACs) inhibitor; Synthetic hydroxamic acids and suberoylanilide hydroxamic acid (SAHA)

Indexed keywords

EID: 79959369753     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch35     Document Type: Chapter

References (70)

1. Allfrey,V. G.; Faulkner, R.; Mirsky,A.E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. USA 1964, 51, 786-794.
2. Roth, S.Y.; Denu, J. M.; Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70, 81-120.
3. Laherty, C. D.; Yang, W. M.; Sun, J. M.; Davie, J. R.; Seto, E.; Eisenman, R. N. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 1997, 89, 349-356.
4. Brehm, A.; Miska, E. A.; McCance, D. J.; Reid, J. L.; Bannister, A. J.; Kouzarides, T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998, 391, 597-601.
5. Wong, J.; Patterton, D.; Imhof, A.; Guschin, D.; Shi, Y. B.; Wolffe, A. P. Distinct requirements for chromatin assembly in transcriptional repression by thyroid hormone receptor and histone deacetylase. EMBO J. 1998, 17, 520-534.
6. Yang,W. M.; Inouye, C.; Zeng,Y.; Bearss, D.; Seto, E. Transcriptional repression ofYY1is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc. Natl. Acad. Sci. USA 1996, 93, 12845-12850.
7. Gregoretti, I.V.; Lee,Y. M.; Goodson, H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 338, 17-31.
8. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38-51.
9. Bode, A. M.; Dong, Z. Post-translational modification of p52 in tumorigenesis. Nat. Rev. Cancer 2004, 4, 793-805.
10. Chen, L. F.; Greene, W. C. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J. Mol. Med. 2003, 81, 549-557.
11. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22, 1168-1179.
12. Kovacs, J. J.; Murphy, P. J.; Gaillard, S.; Zhao, X.;Wu, J. T.; Nicchitta, C. V.;Yoshida, M.; Toft, D. O.; Pratt, W. B.; Yao, T. P. HDAC6 regulates Hsp90 acetylation and chaperonedependent activation of glucocorticoid receptor. Mol. Cell 2005, 18, 601-607.
13. Zhang, C. L.; McKinsey, T. A.; Chang, S.; Antos, C. L.; Hill, J. A.; Olsen, E. N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110, 479-488.
14. Zhang, Y.; Kwon, S.; Yamaguchi, T.; Cubizolles, F.; Rousseaux, S.; Kneissel, M.; Cao, C.; Li, N.; Cheng, H. L.; Chua, K.; Lombard, D.; Mizeracki, A.; Matthias, G.; Alt, F. W.; Khochbin, S.; Matthias, P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 2008, 28, 1688-1701.
15. Tsuji, N.; Kobayashi, M.; Nagashima, K.; Wakisaki, Y.; Koizumi, K. A new antifungal antibiotic, trichostatin. J. Antibiot. 1976, 29, 1-6.
16. Yoshida, M.; Beppu, T. Reversible arrest of proliferation of rat 3Y1 fibroblasts in both G1 and G2 phases by trichostatin A. Exp. Cell Res. 1988, 177, 122-131.
17. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
18. Hoshikawa,Y.;Kwon, H. J.;Yoshida, M.; Horinouchi, S.; Beppu, T. TrichostatinAinduces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp. Cell Res. 1994, 214, 189-197.
19. Mielnicki, L. M.; Ying, A. M.; Head, K. L.; Asch, H. L.; Asch, B. B. Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp. Cell Res. 1999, 249, 161-176.
20. Kwon, H. J.; Owa, T.; Hassig, C. H.; Shimada, J.; Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA 1998, 95, 3356-3361.
21. Matsumoto, M.; Matsutani, S.; Sugita, K.; Yoshida, H.; Hayashi, F.; Terui, Y.; Nakai, H.; Uotani, N.; Kawamura, Y.; Matsumoto, K. Depudecin: a novel compound inducing the flat phenotype of NIH3T3 cells doubly transformed by ras- and src-oncogene, produced by Alternaria brassicicola. J. Antibiot. 1992, 45, 879-885.
22. Kijima, M.; Yosjida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
23. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R.W.; Dulski, P. M.; Crumley, T. M.; Allocco, J. J.; Cannova, C.; Meinke, P. T.; Colletti, S. L.; Bednarek, M. A.; Singh, S. B.; Goetz, M. A.; Dombrowski, A.W.; Polishook, J. D.; Schmatz, D. M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 1996, 93, 13143-13147.
24. Ueda, H.; Nakajima, H.; Hori, Y.; Fujita, T.; Nishimura, M.; Goto, T.; Okuhara, M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. 1994, 47, 30-310.
25. Newmark, H. L.; Lupton, J. R.; Young, C. W. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. 2001, 78, 1-5.
26. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
27. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA 101 2004, 15064-15069.
28. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfi, A.; Defrancesco, R.; Steinkuhler, C.; Di Marco, S. Substrate binding to histone deacetylases as revealed by crystal structure of HDAC8-substrate complex. EMBO Rep. 2008, 8, 879-884.
29. Richon, V. M.; Emiliani, S.; Verdin, E.;Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 1998, 95, 3003-3007.
30. Belvedere, S.; Witter, D. J.; Yan, Y.; Secrist, P.; Richon, V.; Miller, T. A. Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 3969-3971.
31. Miller, T. A.;Witter, D. J.; Belvedere, S. Diamine and iminodiacetic acid hydroxamic acid derivatives. WO2005053610, 2005.
32. Finn, P.W.; Bandara, M.; Butcher, C.; Finn, A.; Hollinshead, R.; Khan, N.; Law,N.; Murthy, S.; Romero, R.; Watkins, C.; Andrianov, V.; Bokaldere, R. M.; Dikovska, K.; Gailite, V.; Loza, E.; Piskunova, I.; Starchenkov, I.; Vorona, M.; Kalvinsh, I. Novel sulphonamide derivatives as inhibitors of histone deacetylase. Helv. Chim. Acta 2005, 88, 1630-1657.
33. Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 1999, 42, 3001-3003.
34. Siliphaivanh, P.; Harrington, P.;Witter, D. J.; Otte, K.; Tempest, P.; Kattar, S.; Kral, A. M.; Fleming, J. C.; Deshmukh, S. V.; Harsch, A.; Secrist, P. J.; Miller, T. A. Design of novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4619-4624.
35. Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomoya, S.-I.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3313-3317.
36. Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. Novel inhibitors of histone deacetylases: design, synthesis, enzyme inhibition and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem. 2005, 48, 1019-1032.
37. Gu, W.; Nusinzon, I.; Smith, R. D.; Horvath, C. M.; Silverman, R. B. Carbonyl- and sulphur-containing analogs of suberoylamide hydroxamic acid: potent inhibition of histone deacetylases. Bioorg. Med. Chem. Lett. 2006, 14, 3320-3329.
38. Wada, K. C.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Garland, R. B.; Holms, J. H.; Li, J.; Pease, L. J.; Guo, J.; Glaser, K. B.; Marcotte, P. A.; Richardson, P. L.; Murphy, S. S.; Bouska, J. J.; Tapang, P.; Magoc, T. J.; Albert, D. H.; Davidsen, S. K.; Michaelides, M. R. a-Keto amides as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 2003, 13, 3331-3335.
39. Vasudevan, A.; Ji, Z.; Frey, R. R.; Wada, K. C.; Steinman, D.; Heyman, H. R.; Guo, Y.; Curtin, M. L.; GGuo, J.; Li, J.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Albert, D. H.; Davidsen, S. K.; Michaelides, M. R. Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 2003, 13, 3909-3913.
40. Jones, P.; Altamura, S.; De Francesco, R.; Paz, O. G.; Kinzel, O.; Mesiti, G.; Monteagudo, E.; Pescatore, G.; Rowley, M.;Verdirame, M.; Steinkuehler, C. Anovel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem. 2008, 51, 2350-2353.
41. Jones, P.; Bottomley, M. J.; Carfi, A.; Cecchetti, O.; Ferrigno, F.; Lo Surdo, P.; Ontoria, J. M.; Rowley, M.; Scarpelli, R.; Schultz-Fademrecht, C.; Steinkuehler, C. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2008, DOI:10.1016/j.bmcl.2008.02.026.
42. Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 1999, 9, 40-48.
43. Richon, V. M.;Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 1996, 93, 5705-5708.
44. Kim, Y. B.; Lee, K. H.; Sugita, K.; Yoshida, M.; Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999, 18, 2461-2470.
45. Kitamura, K.; Hoshi, S.; Koike, M.; Kiyoi, H.; Saito, H.; Naoe, T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t (11;17) in combination with all-trans retinoic acid. Br. J. Haematol. 2000, 108, 696-702.
46. David, G.; Alland, L.; Hong, S. H.; Wong, C. W.; DePinho, R. A.; Dejean, A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 1998, 16, 2549-2556.
47. Lin, R. J.; Nagy, L.; Inoue, S.; Shao,W.; Miller,W. H., Jr.; Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391, 811-814.
48. Yoshida, M.; Horinouchi, S. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann. N.Y. Acad. Sci. 1999, 886, 23-36.
49. Ueda, H.; Manda, T.; Matsumoto, S.; Mukumoto, S.; Nishigaki, F.; Kawamura, I.; Shimomura, K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. 1994, 47, 315-323.
50. Desai, D.; Das, A.; Cohen, L.; el-Bayoumy, K.; Amin, S. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res. 2003, 23, 499-503.
51. Olsen, E.; Kim,Y. H.; Kuzel, T.,et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): results of a phase IIb trial. J. Clin. Oncol. 2006, 24(18S), ASCO Annual Meeting Proceedings Part I, Abstract 7500.
52. Steele, N. L.; Plumb, J. A.; Vidal, L.; Tjornelund, J.; Knoblauch, P.; Rasmussen, A.; Ooi, C. E.; Buhl-Jensen, P.; Brown, R.; Evans, T. R. J.; De Bono, J. S. Aphase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 804-810.
53. Piekarz, R. L.; Robey, R.; Sandor,V.; Bakke, S.;Wilson,W. H.; Dahmoush, L.; Kingma, D. M.; Turner,M. L.; Altemus, R.; Bates, S. E. Inhibitor of histone deacetylase, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001, 98, 2865-2868.
54. Shah, M. H.; Binkley, P.; Chan, K.; Xiao, J.; Arbogast, D.; Collamore, M.; Farra,Y.;Young, D.; Grever, M. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 2006, 12, 3997-4003.
55. Zhu, W.-G.; Lakshmanan, R. R.; Beal, M. D.; Otterson, G. A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2001, 61, 1327-1333.
56. Plumb, J. A.; Steele, N.; Finn, P. W.; Brown, R. Epigenetic approaches to cancer therapy. Biochem. Soc. Trans. 2004, 32, 1095-1097.
57. Tumber, A.; Collins, L. S.; Petersen, K. D.; Thougaard, A.; Christiansen, S. J.; Dejligbjerg, M.; Buhl Jensen, P.; Sehested, M.; Ritchie, J. W. A. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother. Pharmacol. 2007, 60, 275-283.
58. Leoni, F.; Zaliani, A.; Bertolini, G.; Porro, G.; Pagani, P.; Pozzi, P.; Doná, G.; Fossati, G.; Sozzani, S.; Azam, T.; Bufler, P.; Fantuzzi, G.; Goncharo, I.; Kim, S. H.; Pomerantz, B. J.; Reznikov, L. L.; Siegmund, B.;Dinarello, C. A.;Mascagni, P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 2002, 99, 2995-3000.
59. Chung, Y.-L.; Lee, M.-Y.; wang, A.-J.; Yao, L.-F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 2003, 8, 707-717.
60. Saunders, N.; Dicker, A.; Popa, C.; Jones, S.; Dahler, A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 1999, 59, 399-404.
61. Takahashi, I.; Miyaji, H.; Yoshida, T.; Sato, S.; Mizukami, T. Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J. Antibiot. 1996, 49, 453-457.
62. Kim, M. S.; Kwon, H. J.; Lee, Y. M.; Baek, J. H.; Jang, J. E.; Lee, S.W.; Moon, E. J.; Kim, H. S.; Lee, S. K.; Chung, H. Y.; Kim, C. W.; Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001, 7, 437-443.
63. Adcock, I. M. HDAC inhibitors as anti-inflammatory agents. Br. J. Pharmacol. 2007, 150, 829-831.
64. Sadri-Vakili, G.; Bouzou, B.; Benn, C. L.; Kim, M. O.; Chawla, P.; Overland, R. P.; Glajch, K. E.; Xia, E.; Qiu, Z.; Hersch, S. M.; Clark, T. W.; Yohrling, G. J.; Cha, J. H. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 2007, 16, 1293-1306.
65. Hockly, E.; Richon,V. M.;Woodman, B.; Smith, D. L.; Zhou, X.; Rosa, E.; Sathasivam, K.; Ghazi-Noori, S.; Mahal, A.; Lowden, P. A.; Steffan, J. S.; Marsh, J. L.; Thompson, L. M.; Lewis, C. M.; Marks, P. A.; Bates, G. P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2003, 100, 2041-2046.
66. Mai, A.; Cerbara, I.; Valente, S.; Massa, S.;Walker, L. A.; Tekwani, B. L. Antimalarial and antileishmanial activities of aroyl-pyrrolyl-hydroxyamides, a new class of histone deacetylase inhibitors. Antimicrob. Agents Chemother. 2004, 48, 1435-1436.
67. Mukherjee, P.; Pradhan, A.; Shah, F.; Tekwani, B. L.; Avery,M. A. Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): a novel target for the development of antimalarial therapy. Bioorg. Med. Chem. 2008, 16, 5254-5365.
68. Grant, S. L.; Gattis, S. G.; Fierke, C. A. Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 2006, 45, 6170-6178.
69. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber,S. L. Domain selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 2003, 100, 4389-4394.
70. Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem. 2008, 51, 2898-906.